{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:08Z","timestamp":1791668108947,"version":"4.3.4"},"reference-count":143,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Cystic Fibrosis Foundation (FFC)","award":["FFC#11\/2022"],"award-info":[{"award-number":["FFC#11\/2022"]}]},{"name":"FFC supporting group of Delegazione FFC Ricerca di Cuneo Alba","award":["FFC#11\/2022"],"award-info":[{"award-number":["FFC#11\/2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cystic fibrosis (CF) is the most common fatal genetic disease among Caucasian people, with over 2000 mutations in the CFTR gene. Although highly effective modulators have been developed to rescue the mutant CFTR protein, unresolved inflammation and persistent infections still threaten the lives of patients. While the central role of arachidonic acid (AA) and its metabolites in the inflammatory response is widely recognized, less is known about their impact on immunomodulation and metabolic implications in CF. To this end, here we provided a comprehensive analysis of the AA metabolism in CF. In this context, CFTR dysfunction appeared to complexly disrupt normal lipid processing, worsening the chronic airway inflammation, and compromising the immune responses to bacterial infections. As such, potential strategies targeting AA and its inflammatory mediators are being investigated as a promising approach to balance the inflammatory response while mitigating disease progression. Thus, a deeper understanding of the AA pathway dysfunction in CF may open innovative avenues for designing more effective therapeutic interventions.<\/jats:p>","DOI":"10.3390\/ph17091185","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T09:21:00Z","timestamp":1725873660000},"page":"1185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dysregulation of the Arachidonic Acid Pathway in Cystic Fibrosis: Implications for Chronic Inflammation and Disease Progression"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9635-9322","authenticated-orcid":false,"given":"Simona","family":"D\u2019Orazio","sequence":"first","affiliation":[{"name":"Department of Medical, Oral and Biotechnology Sciences, University \u201cG. d\u2019Annunzio\u201d Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology (CAST), University \u201cG. d\u2019Annunzio\u201d Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-2855","authenticated-orcid":false,"given":"Domenico","family":"Mattoscio","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnology Sciences, University \u201cG. d\u2019Annunzio\u201d Chieti-Pescara, 66100 Chieti, Italy"},{"name":"Center for Advanced Studies and Technology (CAST), University \u201cG. d\u2019Annunzio\u201d Chieti-Pescara, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"ref_1","unstructured":"(2024, July 08). Cystic Fibrosis Mutation Database: Statistics. Available online: http:\/\/www.genet.sickkids.on.ca\/StatisticsPage.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"C1555","DOI":"10.1152\/ajpcell.1998.275.6.C1555","article-title":"Characterization of CFTR Expression and Chloride Channel Activity in Human Endothelia","volume":"275","author":"Tousson","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1021\/bi060490t","article-title":"CFTR Expression in Human Neutrophils and the Phagolysosomal Chlorination Defect in Cystic Fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Porto, P.D., Cifani, N., Guarnieri, S., Domenico, E.G.D., Mariggi\u00f2, M.A., Spadaro, F., Guglietta, S., Anile, M., Venuta, F., and Quattrucci, S. (2011). Dysfunctional CFTR Alters the Bactericidal Activity of Human Macrophages against Pseudomonas Aeruginosa. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019970"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1465-9921-10-26","article-title":"Influence of the Cystic Fibrosis Transmembrane Conductance Regulator on Expression of Lipid Metabolism-Related Genes in Dendritic Cells","volume":"10","author":"Xu","year":"2009","journal-title":"Respir. Res."},{"key":"ref_6","first-page":"3970","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Expression in Human Platelets: Impact on Mediators and Mechanisms of the Inflammatory Response","volume":"24","author":"Mattoscio","year":"2010","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/S0021-9258(19)50722-0","article-title":"Human Lymphocytes Transcribe the Cystic Fibrosis Transmembrane Conductance Regulator Gene and Exhibit CF-Defective cAMP-Regulated Chloride Current","volume":"267","author":"McDonald","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-Resolving Lipid Mediators Are Leads for Resolution Physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Recchiuti, A., Mattoscio, D., and Isopi, E. (2019). Roles, Actions, and Therapeutic Potential of Specialized Pro-Resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00252"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Briottet, M., Shum, M., and Urbach, V. (2020). The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01290"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Shum, M., London, C.M., Briottet, M., Sy, K.A., Baillif, V., Philippe, R., Zare, A., Ghorbani-Dalini, S., Remus, N., and Tarze, A. (2022). CF Patients\u2019 Airway Epithelium and Sex Contribute to Biosynthesis Defects of Pro-Resolving Lipids. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.915261"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin. Chest Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and Addressing the Needs of People with Cystic Fibrosis in the Era of CFTR Modulator Therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 Fatty Acids and Inflammatory Processes: From Molecules to Man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem. Soc. Trans."},{"key":"ref_17","first-page":"3","article-title":"Arachidonic Acid Metabolism: Role in Inflammation","volume":"50","author":"Samuelsson","year":"1991","journal-title":"Z. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.plefa.2010.07.002","article-title":"Fatty Acid Metabolism in Cystic Fibrosis","volume":"83","author":"Strandvik","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism Pathways of Arachidonic Acids: Mechanisms and Potential Therapeutic Targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm.2017.138","article-title":"Understanding the Diversity of Membrane Lipid Composition","volume":"19","author":"Harayama","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0140-6736(78)91746-4","article-title":"Abnormal Levels of Prostaglandins and Fatty Acids in Blood of Children with Cystic Fibrosis","volume":"2","author":"Chase","year":"1978","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ajcn\/54.6.1029","article-title":"Essential Fatty Acid Status and Fluidity of Plasma Phospholipids in Cystic Fibrosis Infants","volume":"54","author":"Johnson","year":"1991","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1042\/CS20220450","article-title":"The Fatty Acid Imbalance of Cystic Fibrosis Exists at Birth Independent of Feeding in Pig and Ferret Models","volume":"136","author":"Uc","year":"2022","journal-title":"Clin. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1203\/00006450-198501000-00028","article-title":"Fatty Acid Abnormalities in Cystic Fibrosis","volume":"19","author":"Farrell","year":"1985","journal-title":"Pediatr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000114208","article-title":"Relation between Fatty Acid Composition and Clinical Status or Genotype in Cystic Fibrosis Patients","volume":"51","author":"Vanbillemont","year":"2007","journal-title":"Ann. Nutr. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s004310050750","article-title":"Essential Fatty Acid Deficiency in Well Nourished Young Cystic Fibrosis Patients","volume":"156","author":"Roulet","year":"1997","journal-title":"Eur. J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.3390\/ijms150916083","article-title":"Abnormal Unsaturated Fatty Acid Metabolism in Cystic Fibrosis: Biochemical Mechanisms and Clinical Implications","volume":"15","author":"Seegmiller","year":"2014","journal-title":"IJMS"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1535370218758605","article-title":"Low Linoleic and High Docosahexaenoic Acids in a Severe Phenotype of Transgenic Cystic Fibrosis Mice","volume":"243","author":"Strandvik","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0022-2275(20)41397-5","article-title":"Cellular Interactions between N-6 and n-3 Fatty Acids: A Mass Analysis of Fatty Acid Elongation\/Desaturation, Distribution among Complex Lipids, and Conversion to Eicosanoids","volume":"33","author":"Rubin","year":"1992","journal-title":"J. Lipid Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMoa021218","article-title":"Association of Cystic Fibrosis with Abnormalities in Fatty Acid Metabolism","volume":"350","author":"Freedman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Shrestha, N., Rout-Pitt, N., McCarron, A., Jackson, C.A., Bulmer, A.C., McAinch, A.J., Donnelley, M., Parsons, D.W., and Hryciw, D.H. (2023). Changes in Essential Fatty Acids and Ileal Genes Associated with Metabolizing Enzymes and Fatty Acid Transporters in Rodent Models of Cystic Fibrosis. IJMS, 24.","DOI":"10.3390\/ijms24087194"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13995","DOI":"10.1073\/pnas.96.24.13995","article-title":"A Membrane Lipid Imbalance Plays a Role in the Phenotypic Expression of Cystic Fibrosis in Cftr\u2212\/\u2212 Mice","volume":"96","author":"Freedman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1194\/jlr.M018101","article-title":"DHA and EPA Reverse Cystic Fibrosis-Related FA Abnormalities by Suppressing FA Desaturase Expression and Activity","volume":"53","author":"Njoroge","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.plefa.2007.12.005","article-title":"Oral DHA Supplementation in \u0394F508 Homozygous Cystic Fibrosis Patients","volume":"78","author":"Devos","year":"2008","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_35","first-page":"431","article-title":"Increased \u03945- and \u03946-Desaturase, Cyclooxygenase-2, and Lipoxygenase-5 Expression and Activity Are Associated with Fatty Acid and Eicosanoid Changes in Cystic Fibrosis","volume":"1811","author":"Njoroge","year":"2011","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.M700388-JLR200","article-title":"Cell Culture Models Demonstrate That CFTR Dysfunction Leads to Defective Fatty Acid Composition and Metabolism","volume":"49","author":"Andersson","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Das, U.N. (2021). Essential Fatty Acids and Their Metabolites in the Pathobiology of Inflammation and Its Resolution. Biomolecules, 11.","DOI":"10.3390\/biom11121873"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/00365518609083706","article-title":"G\u00f6s. Increased Mole Fraction of Arachidonic Acid in Bronchial Phospholipids in Patients with Cystic Fibrosis","volume":"46","author":"Gilljam","year":"1986","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.83.23.9202","article-title":"Pathological Regulation of Arachidonic Acid Release in Cystic Fibrosis: The Putative Basic Defect","volume":"83","author":"Strandvik","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1183\/09031936.00183409","article-title":"Critical Role of Cytosolic Phospholipase A2 in Bronchial Mucus Hypersecretion in CFTR-Deficient Mice","volume":"36","author":"Dif","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Borot, F., Vieu, D.-L., Faure, G., Fritsch, J., Colas, J., Moriceau, S., Baudouin-Legros, M., Brouillard, F., Ayala-Sanmartin, J., and Touqui, L. (2009). Eicosanoid Release Is Increased by Membrane Destabilization and CFTR Inhibition in Calu-3 Cells. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007116"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1074\/mcp.M500019-MCP200","article-title":"Down-Regulation of the Anti-Inflammatory Protein Annexin A1 in Cystic Fibrosis Knock-out Mice and Patients","volume":"4","author":"Bensalem","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2353\/ajpath.2010.091149","article-title":"CFTR Inhibition Provokes an Inflammatory Response Associated with an Imbalance of the Annexin A1 Pathway","volume":"177","author":"Dalli","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/bjp.2008.216","article-title":"Arachidonic Acid and Ion Channels: An Update","volume":"155","author":"Meves","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1139\/y00-014","article-title":"Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Currents by Arachidonic Acid","volume":"78","author":"Linsdell","year":"2000","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2007.02.048","article-title":"Molecular Mechanism of Arachidonic Acid Inhibition of the CFTR Chloride Channel","volume":"563","author":"Zhou","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Dei Cas, M., Zulueta, A., Mingione, A., Caretti, A., Ghidoni, R., Signorelli, P., and Paroni, R. (2020). An Innovative Lipidomic Workflow to Investigate the Lipid Profile in a Cystic Fibrosis Cell Line. Cells, 9.","DOI":"10.3390\/cells9051197"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of Bioactive Lipid Signalling: Lessons from Sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/EBC20200018","article-title":"Specialized Pro-Resolving Mediator Network: An Update on Production and Actions","volume":"64","author":"Chiang","year":"2020","journal-title":"Essays Biochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1073\/pnas.89.13.6147","article-title":"Cytosolic Phospholipase A2 Is Coupled to Hormonally Regulated Release of Arachidonic Acid","volume":"89","author":"Lin","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jcf.2020.01.010","article-title":"Airway Profile of Bioactive Lipids Predicts Early Progression of Lung Disease in Cystic Fibrosis","volume":"19","author":"Horati","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of Inflammation: The Beginning Programs the End","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/archotol.134.8.825","article-title":"Expression of Cyclooxygenase and Lipoxygenase Enzymes in Sinonasal Mucosa of Patients with Cystic Fibrosis","volume":"134","author":"Owens","year":"2008","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/thx.2004.039842","article-title":"Upregulation of COX-1 and COX-2 in Nasal Polyps in Cystic Fibrosis","volume":"61","author":"Pujols","year":"2006","journal-title":"Thorax"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.freeradbiomed.2012.05.001","article-title":"Metabolomic Profiling of Regulatory Lipid Mediators in Sputum from Adult Cystic Fibrosis Patients","volume":"53","author":"Yang","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0952-3278(96)90125-8","article-title":"Prostanoid Biosynthesis in Patients with Cystic Fibrosis","volume":"55","author":"Strandvik","year":"1996","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2125.1987.tb03004.x","article-title":"Detection of Sputum Eicosanoids in Cystic Fibrosis and in Normal Saliva by Bioassay and Radioimmunoassay","volume":"23","author":"Zakrzewski","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","first-page":"1408","article-title":"Prostaglandins E2 and E2 Alpha Are Elevated in Saliva of Cystic Fibrosis Patients","volume":"84","author":"Rigas","year":"1989","journal-title":"Am. J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.plefa.2013.06.001","article-title":"Quantification of Major Urinary Metabolites of PGE2 and PGD2 in Cystic Fibrosis: Correlation with Disease Severity","volume":"89","author":"Jabr","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gartner, S., Roca-Ferrer, J., Fernandez-Alvarez, P., Lima, I., Rovira-Amigo, S., Garc\u00eda-Arumi, E., Tizzano, E.F., and Picado, C. (2024). Elevated Prostaglandin E2 Synthesis Is Associated with Clinical and Radiological Disease Severity in Cystic Fibrosis. J. Clin. Med., 13.","DOI":"10.20944\/preprints202401.0439.v1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1164\/ajrccm.162.4.9911071","article-title":"In Vivo Lipid Peroxidation and Platelet Activation in Cystic Fibrosis","volume":"162","author":"Ciabattoni","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Patrono, C., and Rocca, B. (2019). Measurement of Thromboxane Biosynthesis in Health and Disease. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01244"},{"key":"ref_63","first-page":"491","article-title":"Modulation of Human Neutrophil Function by Monohydroxy-Eicosatetraenoic Acids","volume":"39","author":"Goetzl","year":"1980","journal-title":"Immunology"},{"key":"ref_64","first-page":"541","article-title":"15-Hydroxyeicosatetraenoic Acid Inhibits Neutrophil Migration across Cytokine-Activated Endothelium","volume":"145","author":"Takata","year":"1994","journal-title":"Am. J. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3945\/an.114.007732","article-title":"Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs","volume":"6","author":"Gabbs","year":"2015","journal-title":"Adv. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1748-1716.1980.tb06656.x","article-title":"Identification of 15-Hydroxy-5,8,11,13-Eicosatetraenoic Acid (15-HETE) as a Major Metabolite of Arachidonic Acid in Human Lung","volume":"110","author":"Hamberg","year":"1980","journal-title":"Acta Physiol. Scand."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nri3859","article-title":"Eicosanoid Storm in Infection and Inflammation","volume":"15","author":"Dennis","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp038190","article-title":"From Asthma to Atherosclerosis--5-Lipoxygenase, Leukotrienes, and Inflammation","volume":"350","author":"Zampolli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1067\/mai.2003.25","article-title":"Roles of Cysteinyl Leukotrienes in Airway Inflammation, Smooth Muscle Function, and Remodeling","volume":"111","author":"Holgate","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1021\/cr200246d","article-title":"Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease","volume":"111","author":"Funk","year":"2011","journal-title":"Chem. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/adc.68.3.389","article-title":"Sputum Tumour Necrosis Factor-Alpha and Leukotriene Concentrations in Cystic Fibrosis","volume":"68","author":"Greally","year":"1993","journal-title":"Arch. Dis. Child."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/ajrccm\/148.4_Pt_1.896","article-title":"Leukotriene B4 Markedly Elevated in the Epithelial Lining Fluid of Patients with Cystic Fibrosis","volume":"148","author":"Konstan","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2125.1990.tb05452.x","article-title":"Leukotrienes in the Sputum and Urine of Cystic Fibrosis Children","volume":"30","author":"Sampson","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"458217","DOI":"10.1100\/tsw.2010.113","article-title":"Lipoxin and Aspirin-Triggered Lipoxins","volume":"10","author":"Romano","year":"2010","journal-title":"Sci. World J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8269","DOI":"10.1021\/bi00150a021","article-title":"Lipoxin Generation by Permeabilized Human Platelets","volume":"31","author":"Romano","year":"1992","journal-title":"Biochemistry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/bj2960127","article-title":"Lipoxin Synthase Activity of Human Platelet 12-Lipoxygenase","volume":"296","author":"Romano","year":"1993","journal-title":"Biochem. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.92.21.9475","article-title":"Aspirin Triggers Previously Undescribed Bioactive Eicosanoids by Human Endothelial Cell-Leukocyte Interactions","volume":"92","author":"Claria","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF03401642","article-title":"Aspirin-Triggered Lipoxins (15-Epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)-Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation","volume":"2","author":"Claria","year":"1996","journal-title":"Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"C870","DOI":"10.1152\/ajpcell.1999.277.5.C870","article-title":"Hepatocytes Are a Rich Source of Novel Aspirin-Triggered 15-Epi-Lipoxin A(4)","volume":"277","author":"Titos","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI114503","article-title":"Lipoxin Formation during Human Neutrophil-Platelet Interactions. Evidence for the Transformation of Leukotriene A4 by Platelet 12-Lipoxygenase in Vitro","volume":"85","author":"Serhan","year":"1990","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2015.03.083","article-title":"Lipoxins and Aspirin-Triggered Lipoxins in Resolution of Inflammation","volume":"760","author":"Romano","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ni1056","article-title":"Defective Lipoxin-Mediated Anti-Inflammatory Activity in the Cystic Fibrosis Airway","volume":"5","author":"Karp","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Jeanson, L., Guerrera, I.C., Papon, J.-F., Chhuon, C., Zadigue, P., Pruli\u00e8re-Escabasse, V., Amselem, S., Escudier, E., Coste, A., and Edelman, A. (2014). Proteomic Analysis of Nasal Epithelial Cells from Cystic Fibrosis Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108671"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/09031936.00106013","article-title":"Reduced 15-Lipoxygenase 2 and Lipoxin A4\/Leukotriene B4 Ratio in Children with Cystic Fibrosis","volume":"44","author":"Ringholz","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Pierdomenico, A.M., Patruno, S., Codagnone, M., Simiele, F., Mari, V.C., Plebani, R., Recchiuti, A., and Romano, M. (2017). microRNA-181b Is Increased in Cystic Fibrosis Cells and Impairs Lipoxin A4 Receptor-Dependent Mechanisms of Inflammation Resolution and Antimicrobial Defense. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-14055-y"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"16747","DOI":"10.1073\/pnas.0508081102","article-title":"The Antiinflammatory Effect of Laminar Flow: The Role of PPARgamma, Epoxyeicosatrienoic Acids, and Soluble Epoxide Hydrolase","volume":"102","author":"Liu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-6147(00)01472-3","article-title":"New Role for Epoxyeicosatrienoic Acids as Anti-Inflammatory Mediators","volume":"21","author":"Campbell","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Tooker, B.C., Kandel, S.E., Work, H.M., and Lampe, J.N. (2022). Pseudomonas Aeruginosa Cytochrome P450 CYP168A1 Is a Fatty Acid Hydroxylase That Metabolizes Arachidonic Acid to the Vasodilator 19-HETE. J. Biol. Chem., 298.","DOI":"10.1101\/2021.10.19.465045"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Malhotra, S., Hayes, D., and Wozniak, D.J. (2019). Cystic Fibrosis and Pseudomonas Aeruginosa: The Host-Microbe Interface. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00138-18"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Tunaru, S., Chennupati, R., N\u00fcsing, R.M., and Offermanns, S. (2016). Arachidonic Acid Metabolite 19(S)-HETE Induces Vasorelaxation and Platelet Inhibition by Activating Prostacyclin (IP) Receptor. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163633"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbadis.2011.12.012","article-title":"Oxidative Stress and Antioxidant Therapy in Cystic Fibrosis","volume":"1822","author":"Galli","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.freeradbiomed.2010.07.010","article-title":"Identifying Peroxidases and Their Oxidants in the Early Pathology of Cystic Fibrosis","volume":"49","author":"Thomson","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.200311-1516OC","article-title":"Myeloperoxidase and Protein Oxidation in the Airways of Young Children with Cystic Fibrosis","volume":"170","author":"Kettle","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000136357","article-title":"Oxidative Innate Immune Defenses by Nox\/Duox Family NADPH Oxidases","volume":"15","author":"Rada","year":"2008","journal-title":"Contrib. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1152\/jappl.1993.75.6.2419","article-title":"Systemic Deficiency of Glutathione in Cystic Fibrosis","volume":"75","author":"Roum","year":"1993","journal-title":"J. Appl. Physiol. (1985)"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/ars.2009.2597","article-title":"Generation and Biological Activities of Oxidized Phospholipids","volume":"12","author":"Bochkov","year":"2010","journal-title":"Antioxid. Redox Signal"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/ars.2020.8022","article-title":"Inflammation, Lipid (Per)Oxidation, and Redox Regulation","volume":"33","author":"Dias","year":"2020","journal-title":"Antioxid. Redox Signal"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"L1067","DOI":"10.1152\/ajplung.2001.280.6.L1067","article-title":"Isoprostanes: An Overview and Putative Roles in Pulmonary Pathophysiology","volume":"280","author":"Janssen","year":"2001","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/ars.2005.7.244","article-title":"The Pulmonary Biology of Isoprostanes","volume":"7","author":"Janssen","year":"2005","journal-title":"Antioxid. Redox Signal"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/eji.201545676","article-title":"The Regulation of Inflammation by Oxidized Phospholipids","volume":"46","author":"Freigang","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Galiniak, S., Mo\u0142o\u0144, M., and Rachel, M. (2022). Links between Disease Severity, Bacterial Infections and Oxidative Stress in Cystic Fibrosis. Antioxidants, 11.","DOI":"10.3390\/antiox11050887"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/ajcn\/75.4.668","article-title":"Increased Plasma Fatty Acid Concentrations after Respiratory Exacerbations Are Associated with Elevated Oxidative Stress in Cystic Fibrosis Patients","volume":"75","author":"Wood","year":"2002","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1440-1843.2006.00962.x","article-title":"Oxidative Stress and Lipid-Derived Inflammatory Mediators during Acute Exacerbations of Cystic Fibrosis","volume":"12","author":"Reid","year":"2007","journal-title":"Respirology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1179\/joc.2008.20.2.166","article-title":"Antibiotic Therapy against Pseudomonas Aeruginosa in Cystic Fibrosis","volume":"20","author":"Taccetti","year":"2008","journal-title":"J. Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11745-999-0397-1","article-title":"Elevated Plasma Levels of F2\u03b1 Isoprostane in Cystic Fibrosis","volume":"34","author":"Collins","year":"1999","journal-title":"Lipids"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"41651","DOI":"10.1074\/jbc.M112.405407","article-title":"Novel Keto-Phospholipids Are Generated by Monocytes and Macrophages, Detected in Cystic Fibrosis, and Activate Peroxisome Proliferator-Activated Receptor-\u03b3","volume":"287","author":"Hammond","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_107","first-page":"PA2106","article-title":"Inflammation in Cystic Fibrosis Patients: Study of the Eicosanoid Pathway and Severity Correlations","volume":"58","author":"Gartner","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1067\/mpd.2001.118890","article-title":"Essential Fatty Acid Deficiency in Relation to Genotype in Patients with Cystic Fibrosis","volume":"139","author":"Strandvik","year":"2001","journal-title":"J. Pediatr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0304-4157(84)90005-4","article-title":"The Modification of Mammalian Membrane Polyunsaturated Fatty Acid Composition in Relation to Membrane Fluidity and Function","volume":"779","author":"Stubbs","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Bae, H., Kim, B.R., Jung, S., Le, J., Heide, D.M. van der, Yu, W., Park, S.H., Hilkin, B.M., Gansemer, N.D., and Powers, L.S. (2024, June 27). Arteriovenous Metabolomics in Pigs Reveals CFTR Regulation of Metabolism in Multiple Organs. Available online: https:\/\/www.jci.org\/articles\/view\/174500\/pdf.","DOI":"10.1172\/JCI174500"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1093\/jn\/130.12.2870","article-title":"The \u0394F508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Alters Control of Essential Fatty Acid Utilization in Epithelial Cells","volume":"130","author":"Suh","year":"2000","journal-title":"J. Nutr."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7674","DOI":"10.1074\/jbc.M210277200","article-title":"Transcriptional Adaptation to Cystic Fibrosis Transmembrane Conductance Regulator Deficiency","volume":"278","author":"Xu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Moliteo, E., Sciacca, M., Palmeri, A., Papale, M., Manti, S., Parisi, G.F., and Leonardi, S. (2022). Cystic Fibrosis and Oxidative Stress: The Role of CFTR. Molecules, 27.","DOI":"10.3390\/molecules27165324"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Stahl, M., Dohna, M., Graeber, S.Y., Sommerburg, O., Renz, D.M., Pallenberg, S.T., Voskrebenzev, A., Sch\u00fctz, K., Hansen, G., and Doellinger, F. (2024). Impact of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Children with Cystic Fibrosis and One or Two F508del Alleles. Eur. Respir. J., 2400004.","DOI":"10.1183\/13993003.00004-2024"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjms.2024.02.001","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on Respiratory Colonization in an Adult Cystic Fibrosis Clinic","volume":"367","author":"Szabo","year":"2024","journal-title":"Am. J. Med. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e138722","DOI":"10.1172\/jci.insight.138722","article-title":"Distinctive Lipid Signatures of Bronchial Epithelial Cells Associated with Cystic Fibrosis Drugs, Including Trikafta","volume":"5","author":"Liessi","year":"2020","journal-title":"JCI Insight"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcf.2016.07.006","article-title":"The Effects of Ivacaftor on CF Fatty Acid Metabolism: An Analysis from the GOAL Study","volume":"16","author":"Seegmiller","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Veltman, M., De Sanctis, J.B., Stolarczyk, M., Klymiuk, N., B\u00e4hr, A., Brouwer, R.W., Oole, E., Shah, J., Ozdian, T., and Liao, J. (2021). CFTR Correctors and Antioxidants Partially Normalize Lipid Imbalance but Not Abnormal Basal Inflammatory Cytokine Profile in CF Bronchial Epithelial Cells. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.619442"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Teopompi, E., Ris\u00e9, P., Pisi, R., Buccellati, C., Aiello, M., Pisi, G., Tripodi, C., Fainardi, V., Clini, E., and Chetta, A. (2019). Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00938"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ayats-Vidal, R., Bosque-Garc\u00eda, M., Cordobilla, B., Asensio-De la Cruz, O., Garc\u00eda-Gonz\u00e1lez, M., Castro-Marrero, J., L\u00f3pez-Rico, I., and Domingo, J.C. (2023). Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. J. Clin. Med., 12.","DOI":"10.3390\/jcm12113704"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102186","DOI":"10.1016\/j.plefa.2020.102186","article-title":"Long-Term Docosahexaenoic Acid (DHA) Supplementation in Cystic Fibrosis Patients: A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial","volume":"162","author":"Garriga","year":"2020","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_122","first-page":"CD002201","article-title":"Omega-3 Fatty Acid Supplementation for Cystic Fibrosis","volume":"2020","author":"Watson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ayats-Vidal, R., Bosque-Garc\u00eda, M., Cordobilla, B., Asensio-De la Cruz, O., Garc\u00eda-Gonz\u00e1lez, M., Loureda-P\u00e9rez, S., Fern\u00e1ndez-L\u00f3pez, E., Robert-Barriocanal, E., Valiente-Planas, A., and Domingo, J.C. (2024). Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. Nutrients, 16.","DOI":"10.3390\/nu16070970"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"L597","DOI":"10.1152\/ajplung.00257.2010","article-title":"Linoleic Acid Supplement in Cystic Fibrosis: Friend or Foe?","volume":"299","author":"Vij","year":"2010","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of High-Dose Ibuprofen in Patients with Cystic Fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcf.2014.06.001","article-title":"Ibuprofen Rescues Mutant Cystic Fibrosis Transmembrane Conductance Regulator Trafficking","volume":"14","author":"Carlile","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Shah, P.N., Shah, K.N., Smolen, J.A., Tagaev, J.A., Torrealba, J., Zhou, L., Zhang, S., Zhang, F., Wagers, P.O., and Panzner, M.J. (2018). A Novel in Vitro Metric Predicts in Vivo Efficacy of Inhaled Silver-Based Antimicrobials in a Murine Pseudomonas Aeruginosa Pneumonia Model. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-24200-w"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Chen, Q., Ilanga, M., Simbassa, S.B., Chirra, B., Shah, K.N., and Cannon, C.L. (2023). Synergistic Antimicrobial Effects of Ibuprofen Combined with Standard-of-Care Antibiotics against Cystic Fibrosis Pathogens. Biomedicines, 11.","DOI":"10.3390\/biomedicines11112936"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 Inhibitors and Cardiovascular Risk","volume":"50","author":"Funk","year":"2007","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_130","first-page":"97","article-title":"New Mechanisms for Effects of Anti-Inflammatory Glucocorticoids","volume":"3","author":"Bailey","year":"1991","journal-title":"Biofactors"},{"key":"ref_131","first-page":"CD001915","article-title":"Inhaled Corticosteroids for Cystic Fibrosis","volume":"2000","author":"Dezateux","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"32049","DOI":"10.1074\/jbc.R500007200","article-title":"Leukotriene B4 Receptor and the Function of Its Helix 8*","volume":"280","author":"Okuno","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00148581-200507060-00004","article-title":"Leukotriene Receptor Antagonists in Children with Cystic Fibrosis Lung Disease: Anti-Inflammatory and Clinical Effects","volume":"7","author":"Zielen","year":"2005","journal-title":"Paediatr. Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cts.12428","article-title":"Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis","volume":"10","author":"Elborn","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcf.2021.08.007","article-title":"Empire-CF Study: A Phase 2 Clinical Trial of Leukotriene A4 Hydrolase Inhibitor Acebilustat in Adult Subjects with Cystic Fibrosis","volume":"20","author":"Elborn","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0952-3278(03)00072-3","article-title":"The Cysteinyl Leukotriene Receptors","volume":"69","author":"Evans","year":"2003","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/thorax.56.3.244a","article-title":"Montelukast Sodium in Cystic Fibrosis","volume":"56","author":"Morice","year":"2001","journal-title":"Thorax"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1081-1206(10)62108-4","article-title":"Anti-Inflammatory Effects of Montelukast in Mild Cystic Fibrosis","volume":"89","author":"Eickmeier","year":"2002","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1081-1206(10)61156-8","article-title":"Effects of Montelukast Treatment on Clinical and Inflammatory Variables in Patients with Cystic Fibrosis","volume":"95","author":"Stelmach","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.rmed.2006.07.006","article-title":"Effects of Long-Term Treatment with Montelukast in Mild Cystic Fibrosis: (Long Term Treatment with Montelukast in Cystic Fibrosis)","volume":"101","author":"Eickmeier","year":"2007","journal-title":"Respir. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1569-1993(02)00142-X","article-title":"A Pilot Study of Zafirlukast as an Anti-Inflammatory Agent in the Treatment of Adults with Cystic Fibrosis","volume":"2","author":"Conway","year":"2003","journal-title":"J. Cyst. Fibros."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.freeradbiomed.2005.03.032","article-title":"Inhaled Glutathione Decreases PGE2 and Increases Lymphocytes in Cystic Fibrosis Lungs","volume":"39","author":"Hartl","year":"2005","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41467-018-05800-6","article-title":"Resolution of Chronic Inflammatory Disease: Universal and Tissue-Specific Concepts","volume":"9","author":"Schett","year":"2018","journal-title":"Nat. Commun."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/9\/1185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:52:11Z","timestamp":1760111531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/9\/1185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":143,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ph17091185"],"URL":"https:\/\/doi.org\/10.3390\/ph17091185","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}